MX2020007633A - Péptidos macrocíclicos contra acinetobacter baumannii. - Google Patents

Péptidos macrocíclicos contra acinetobacter baumannii.

Info

Publication number
MX2020007633A
MX2020007633A MX2020007633A MX2020007633A MX2020007633A MX 2020007633 A MX2020007633 A MX 2020007633A MX 2020007633 A MX2020007633 A MX 2020007633A MX 2020007633 A MX2020007633 A MX 2020007633A MX 2020007633 A MX2020007633 A MX 2020007633A
Authority
MX
Mexico
Prior art keywords
sup
acinetobacter baumannii
against acinetobacter
peptide macrocycles
macrocycles against
Prior art date
Application number
MX2020007633A
Other languages
English (en)
Inventor
taishan Hu
Theodor Stoll
Konrad Bleicher
Giorgio Patrick Di
Patrizio Mattei
Petra Schmitz
Daniella Cheang
Christian Jenny
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2020007633A publication Critical patent/MX2020007633A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona compuestos de fórmula (I): (ver fórmula I) en la que X1, X2, R1 a R6 y A son tal como se indica en la presente memoria, así como sales farmacéuticamente aceptables de los mismos. Además, la presente invención se refiere a la preparación de los compuestos de fórmula (I), composiciones farmacéuticas que los comprenden y a su utilización como medicamentos destinados al tratamiento de enfermedades e infecciones causadas por bacterias.
MX2020007633A 2018-04-23 2019-04-23 Péptidos macrocíclicos contra acinetobacter baumannii. MX2020007633A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/084131 2018-04-23
PCT/EP2019/060272 WO2019206853A1 (en) 2018-04-23 2019-04-23 Peptide macrocycles against acinetobacter baumannii

Publications (1)

Publication Number Publication Date
MX2020007633A true MX2020007633A (es) 2020-09-14

Family

ID=66290410

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007633A MX2020007633A (es) 2018-04-23 2019-04-23 Péptidos macrocíclicos contra acinetobacter baumannii.

Country Status (19)

Country Link
US (2) US11819532B2 (es)
EP (1) EP3784262A1 (es)
JP (2) JP7460541B2 (es)
KR (1) KR20210005574A (es)
CN (1) CN111886020B (es)
AR (1) AR114290A1 (es)
AU (1) AU2019260124A1 (es)
BR (1) BR112020021729A2 (es)
CA (1) CA3089688A1 (es)
CL (1) CL2020002695A1 (es)
CR (1) CR20200488A (es)
IL (2) IL309537A (es)
MA (1) MA52352A (es)
MX (1) MX2020007633A (es)
PE (1) PE20210855A1 (es)
PH (1) PH12020551762A1 (es)
SG (1) SG11202007219PA (es)
UA (1) UA126943C2 (es)
WO (1) WO2019206853A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3368544B1 (en) 2015-10-27 2020-06-17 H. Hoffnabb-La Roche Ag Peptide macrocycles against acinetobacter baumannii
US11505573B2 (en) 2018-03-28 2022-11-22 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US11819532B2 (en) * 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
JP7458324B2 (ja) 2018-04-23 2024-03-29 セルジーン コーポレイション 置換された４－アミノイソインドリン－１，３－ジオン化合物、及びリンパ腫の治療のためのそれらの使用
EP3934756A1 (en) 2019-03-08 2022-01-12 F. Hoffmann-La Roche AG Novel imidazole-pyrazole derivatives
CN114981259A (zh) 2020-01-22 2022-08-30 豪夫迈·罗氏有限公司 新型杂环化合物
JP2023523962A (ja) 2020-04-29 2023-06-08 エフ． ホフマン－ラ ロシュ アーゲー 抗菌８－フェニルアミノ－３－（ピラゾール－４－イル）イミダゾ［１，２－ａ］ピラジン誘導体
WO2021244997A1 (en) 2020-06-01 2021-12-09 F. Hoffmann-La Roche Ag Novel imidazopyrazne derivatives
EP4161930A1 (en) 2020-06-08 2023-04-12 F. Hoffmann-La Roche AG Novel imidazo-pyrazine derivatives
EP4161931A1 (en) 2020-06-09 2023-04-12 F. Hoffmann-La Roche AG Novel imidazopyrazine derivatives
JP2023538969A (ja) 2020-08-31 2023-09-12 エフ． ホフマン－ラ ロシュ アーゲー 抗菌薬としてのイミダゾール－ピラゾール誘導体
JP2023540307A (ja) 2020-09-01 2023-09-22 エフ． ホフマン－ラ ロシュ アーゲー 抗菌特性を有するイミダゾール－ピラゾール誘導体
WO2022049272A1 (en) 2020-09-07 2022-03-10 F. Hoffmann-La Roche Ag Novel heterocyclic antibiotics
JP2024506021A (ja) 2021-02-07 2024-02-08 エフ． ホフマン－ラ ロシュ アーゲー 新規ヘテロアリール置換イミダゾール誘導体
CN117715892A (zh) 2021-07-06 2024-03-15 豪夫迈·罗氏有限公司 用于治疗细菌感染的季铵阳离子取代化合物
WO2023285497A1 (en) 2021-07-15 2023-01-19 F. Hoffmann-La Roche Ag Imidazole derivatives and their use as antibiotics
AU2023217269A1 (en) * 2022-02-14 2024-05-16 F. Hoffmann-La Roche Ag Process for manufacturing macrocyclic peptides
WO2023161316A1 (en) 2022-02-25 2023-08-31 F. Hoffmann-La Roche Ag Zwitterionic antibacterial compounds
WO2023194418A1 (en) 2022-04-07 2023-10-12 F. Hoffmann-La Roche Ag Crystalline forms of a macrocyclic peptide antibiotic
WO2024033278A1 (en) 2022-08-09 2024-02-15 F. Hoffmann-La Roche Ag Process for manufacturing an antibiotic macrocyclic peptide

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660832B1 (en) 1999-08-20 2003-12-09 Isis Pharmaceuticals, Inc. Macrocyclic compounds and preparation methods thereof
DE10226921A1 (de) 2002-06-17 2003-12-24 Bayer Ag Antibakterielle Amid-Makrozyklen
DE10234422A1 (de) 2002-07-29 2004-02-12 Bayer Ag Antibakterielle Ester-Makrozyklen
ES2281692T3 (es) 2002-08-23 2007-10-01 Sloan-Kettering Institute For Cancer Research Sintesis de epotilones, sus intermediarios, sus analogos y sus usos.
DE602004025569D1 (de) 2003-06-18 2010-04-01 Tranzyme Pharma Inc Makrozyklische motilin rezeptorantagonisten
US7491695B2 (en) 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
EP1498422A1 (de) 2003-07-17 2005-01-19 Jerini AG C5a-Rezeptor-Antagonisten
JP4928263B2 (ja) 2003-07-31 2012-05-09 トランザイム・ファーマ ペプチド結合サロゲートを組み入れた空間的に規定された大環状分子
AU2004261329B2 (en) 2003-07-31 2011-10-27 Ocera Therapeutics, Inc. Spatially-defined macrocyclic compounds useful for drug discovery
WO2005033129A1 (de) 2003-10-01 2005-04-14 Bayer Healthcare Ag Antibakterielle amid-makrozyklen
WO2005090388A1 (en) 2004-03-19 2005-09-29 The University Of Queensland Alpha helical mimics, their uses and methods for their production
DE102004025731A1 (de) 2004-05-26 2005-12-15 Bayer Healthcare Ag Antibakterielle Amid-Makrozyklen III
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
SG158191A1 (en) 2005-01-17 2010-01-29 Jerini Ag C5a receptor antagonists
DE102005014245A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Antibakterielle Amid-Makrozyklen V
GB0609492D0 (en) * 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
JP5554569B2 (ja) 2007-02-08 2014-07-23 ヤンセン・アールアンドデイ・アイルランド ピリミジン置換された大環状ｈｃｖ阻害剤
JP2011511076A (ja) 2008-02-08 2011-04-07 エイルロン セラピューティクス，インコーポレイテッド 治療用ペプチド模倣大環状分子
EP2350031A2 (en) 2008-08-20 2011-08-03 Ensemble Therapeutics Corporation Macrocyclic compounds for inhibition of tumor necrosis factor alpha
WO2011050276A1 (en) 2009-10-23 2011-04-28 Tranzyme Pharma, Inc. Methods of using macrocyclic inhibitors of serine protease enzymes
EP2493910A1 (en) 2009-10-30 2012-09-05 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
JP2013535514A (ja) 2010-08-13 2013-09-12 エイルロン セラピューティクス，インコーポレイテッド ペプチド模倣大環状分子
US20130123196A1 (en) 2011-08-31 2013-05-16 New York University Thioether-, ether-, and alkylamine-linked hydrogen bond surrogate peptidomimetics
CN104159595A (zh) 2012-02-15 2014-11-19 爱勒让治疗公司 拟肽大环化合物
CN103387601B (zh) 2012-05-11 2017-01-11 南开大学 抗登革热病毒(denv)杂环肽类化合物及其制备方法和用途
WO2014048976A1 (en) * 2012-09-25 2014-04-03 Vaxdyn Sl Anti-acinetobacter baumannii immunogens
EP2922829B1 (en) 2012-11-21 2021-08-11 RQX Pharmaceuticals, Inc. Macrocyclic broad spectrum antibiotics
US9493510B2 (en) 2013-01-10 2016-11-15 Noliva Therapeutics Llc Peptidomimetic compounds
EP2942389A1 (en) * 2014-05-05 2015-11-11 Servicio Andaluz De Salud Vaccine against Acinetobacter baumannii based on lipopolysaccharide-deficient cellular components
PT3174852T (pt) 2014-07-30 2018-10-23 Abac Therapeutics S L Aril-hidrazidas contendo uma unidade 2-piridona como agentes antibacterianos seletivos
EP3368544B1 (en) 2015-10-27 2020-06-17 H. Hoffnabb-La Roche Ag Peptide macrocycles against acinetobacter baumannii
EP3388444A1 (en) 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Anti-bacterial peptide macrocycles and use thereof
US11505573B2 (en) 2018-03-28 2022-11-22 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US11819532B2 (en) 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii

Also Published As

Publication number Publication date
CL2020002695A1 (es) 2021-02-19
CN111886020B (zh) 2024-04-05
SG11202007219PA (en) 2020-08-28
US20240050516A1 (en) 2024-02-15
IL309537A (en) 2024-02-01
JP7460541B2 (ja) 2024-04-02
CR20200488A (es) 2021-02-26
TW201945386A (zh) 2019-12-01
MA52352A (fr) 2021-03-03
US11819532B2 (en) 2023-11-21
CN111886020A (zh) 2020-11-03
PE20210855A1 (es) 2021-05-18
CA3089688A1 (en) 2019-10-31
IL278053A (en) 2020-11-30
KR20210005574A (ko) 2021-01-14
BR112020021729A2 (pt) 2021-01-26
WO2019206853A1 (en) 2019-10-31
US20190321440A1 (en) 2019-10-24
JP2021522210A (ja) 2021-08-30
UA126943C2 (uk) 2023-02-22
AU2019260124A1 (en) 2020-08-06
PH12020551762A1 (en) 2021-06-14
EP3784262A1 (en) 2021-03-03
IL278053B2 (en) 2024-05-01
AR114290A1 (es) 2020-08-12
JP2024050700A (ja) 2024-04-10
IL278053B1 (en) 2024-01-01

Similar Documents

Publication Publication Date Title
CR20200488A (es) Péptidos macrocíclicos contra actinetobacter baumannii
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
EP4241772A3 (en) Process for the preparation of compounds useful for treating spinal muscular atrophy
WO2021147236A9 (zh) 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MX2016015248A (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
MX2023004920A (es) Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6).
MX2022015886A (es) Derivados de amidopirimidona.
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
PH12020550168A1 (en) Griseofulvin compound and pharmaceutical use thereof
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX2021014372A (es) Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos.
GEP20237522B (en) Antibacterial compounds
CR20210513A (es) Compuestos de haxahidro 1-h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
SA519401614B1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.
MX2022016455A (es) Derivados de sulfona.
MX2021014544A (es) Derivados de aminoglucosidos antibacterianos.
MX2023008562A (es) Derivados de pirazolamida.
EA202193266A1 (ru) Антибактериальные производные аминогликозидов
ZA202206436B (en) Macrocyclic pantetheine derivatives and uses thereof
MX2023010241A (es) Derivados de alfa-d-galatopiranosido triazolil-metil sustituidos.